Determinants of multidrug-resistant tuberculosis clusters, California, USA, 2004-2007

Emerging Infectious Diseases

Volumn 16, Issue 9, 2010, Pages 1403-1409

  Metcalfe, John Z ^a   Kim, Elizabeth Y ^a   Grace Lin, S Y ^b   Cattamanchi, Adithya ^a   Oh, Peter ^b   Flood, Jennifer ^b   Hopewell, Philip C ^a   Kato Maeda, Midori ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ARTICLE; BACTERIAL STRAIN; CLUSTER ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POPULATION RESEARCH; TREND STUDY; UNITED STATES;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CALIFORNIA; CATALASE; CLUSTER ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENES, BACTERIAL; GENOTYPE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; POINT MUTATION; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 77956031437     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1609.100253     Document Type: Article

References (40)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response [cited 2010 Jun 21]. http://www.who.int/tb/features_archive/world_tb_day_2010/en/index.html
2. Nava-Aguilera E, Andersson N, Harris E, Mitchell S, Hamel C, Shea B, et al. Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009;13:17-26.
3. Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med. 2009;150:766-75.
4. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol. 2009;7:81-7. DOI: 10.1038/nrmicro2048
5. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis. 2007;7:328-37. DOI: 10.1016/S1473-3099 (07)70108-1
6. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, Hopewell PC, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog. 2006;2:e61. DOI: 10.1371/journal.ppat.0020061
7. van Doorn HR, de Haas PE, Kremer K, Vandenbroucke-Grauls CM, Borgdorff MW, van Soolingen D. Public health impact of isoniazid- resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in the Netherlands. Clin Microbiol Infect. 2006;12:769-75.
8. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis. 2000;182:1788-90. DOI: 10.1086/317598
9. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun. 2002;70:4955-60. DOI: 10.1128/IAI.70.9.4955-4960.2002
10. Ang CF, Ong CS, Rukmana A, Pham Thi KL, Yap SF, Ngeow YF, et al. An overview of the phenotypic and genotypic characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from four Asian countries. J Med Microbiol. 2008;57:1039-40. DOI: 10.1099/ jmm.0.47850-0
11. Tracevska T, Jansone I, Baumanis V, Marga O, Lillebaek T. Prevalence of Beijing genotype in Latvian multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis. 2003;7:1097-103.
12. Lipin MY, Stepanshina VN, Shemyakin IG, Shinnick TM. Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia. Clin Microbiol Infect. 2007;13:620-6. DOI: 10.1111/j.1469-0691.2007.01711.x
13. Marttila HJ, Soini H, Eerola E, Vyshnevskaya E, Vyshnevskiy BI, Otten TF, et al. A Ser315Thr substitution in katG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia. Antimicrob Agents Chemother. 1998;42:2443-5.
14. Valvatne H, Syre H, Kross M, Stavrum R, Ti T, Phyu S, et al. Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. J Antimicrob Chemother. 2009;64:694-701. DOI: 10.1093/jac/dkp292
15. Centers for Disease Control and Prevention. Trends in tuberculosis- United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:249-53.
16. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA. 2005;293:2732-9. DOI: 10.1001/jama.293.22.2732
17. Passel JS, Cohn DV. A portrait of unauthorized immigrants in the United States. Washington: Pew Hispanic Center; 2009. p. 2, 13.
18. Sprinson JE, Lawton ES, Porco TC, Flood JM, Westenhouse JL. Assessing the validity of tuberculosis surveillance data in California. BMC Public Health. 2006;6:217. DOI: 10.1186/1471-2458-6-217
19. Lin SY, Probert W, Lo M, Desmond E. Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons. J Clin Microbiol. 2004;42:4204-8. DOI: 10.1128/ JCM.42.9.4204-4208.2004
20. National TB Controllers Association/CDC Advisory Group on Tuberculosis Genotyping. Guide to the application of genotyping to tuberculosis prevention and control. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention; 2004.
21. Cowan LS, Diem L, Brake MC, Crawford JT. Transfer of a Mycobacterium tuberculosis genotyping method, spoligotyping, from a reverse line-blot hybridization, membrane-based assay to the Luminex multianalyte profiling system. J Clin Microbiol. 2004;42:474-7. DOI: 10.1128/JCM.42.1.474-477.2004
22. Cowan LS, Mosher L, Diem L, Massey JP, Crawford JT. Variablenumber tandem repeat typing of Mycobacterium tuberculosis isolates with low copy numbers of IS6110 by using mycobacterial interspersed repetitive units. J Clin Microbiol. 2002;40:1592-602. DOI: 10.1128/JCM.40.5.1592-1602.2002
23. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993;31:406-9.
24. Woelffer GB, Bradford WZ, Paz A, Small PM. A computer-assisted molecular epidemiologic approach to confronting the reemergence of tuberculosis. Am J Med Sci. 1996;311:17-22. DOI: 10.1097/00000441-199601000-00004
25. Tarone RE. On heterogeneity tests based on efficient scores. Biometrika. 1985;72:91-5. DOI: 10.1093/biomet/72.1.91
26. Zelen M. The analysis of several 2 × 2 contingency tables. Biometrika. 1971; 58:129-37.
27. Qian L, Abe C, Lin TP, Yu MC, Cho SN, Wang S, et al. rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J Clin Microbiol. 2002;40:1091-4. DOI: 10.1128/JCM.40.3.1091-1094.2002
28. Marttila HJ, Mäkinen J, Marjamäki M, Ruutu P, Soini H. Molecular genetics of drug-resistant Mycobacterium tuberculosis isolates in Finland, 1995-2004. Int J Tuberc Lung Dis. 2008;12:338-43.
29. Nitta AT, Knowles LS, Kim J, Lehnkering EL, Borenstein LA, Davidson PT, et al. Limited transmission of multidrug-resistant tuberculosis despite a high proportion of infectious cases in Los Angeles County, California. Am J Respir Crit Care Med. 2002;165:812-7.
30. Sun YJ, Lee AS, Wong SY, Heersma H, Kremer K, van Soolingen D, et al. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Int J Tuberc Lung Dis. 2007;11:436-42.
31. Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL. Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis. 2003;188:1878-84. DOI: 10.1086/379895
32. Vazquez-Gallardo R, Anibarro L, Fernandez-Villar A, Diaz-Cabanela D, Cruz-Ferro E, Perez del Molino ML, et al. Multidrugresistant tuberculosis in a low-incidence region shows a high rate of transmission. Int J Tuberc Lung Dis. 2007;11:429-35.
33. Oeltmann JE, Varma JK, Ortega L, Liu Y, O'Rourke T, Cano M, et al. Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg Infect Dis. 2008;14:1715-21. DOI: 10.3201/eid1411.071629
34. Comas I, Gagneux S. The past and future of tuberculosis research. PLoS Pathog. 2009;5:e1000600. DOI: 10.1371/journal. ppat.1000600
35. Nicol MP, Wilkinson RJ. The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg. 2008;102:955-65. DOI: 10.1016/j.trstmh.2008.03.025
36. Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006;50:2640-9. DOI: 10.1128/AAC.00112-06
37. Afanas'ev MV, Ikryannikova LN, Il'ina EN, Sidorenko SV, Kuz'min AV, Larionova EE, et al. Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation. J Antimicrob Chemother. 2007;59:1057-64. DOI: 10.1093/jac/dkm086
38. Hillemann D, Kubica T, Agzamova R, Venera B, Rusch-Gerdes S, Niemann S. Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains isolated from patients in Kazakhstan. Int J Tuberc Lung Dis. 2005;9:1161-7.
39. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312:1944-6. DOI: 10.1126/science. 1124410
40. Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med. 2005;353:1008-20. DOI: 10.1056/ NEJMsa043194